Abstract:Objective: To identify the factors associated with long-term survival and guide the decision for primary surgery in patients with advanced high-grade serous ovarian cancer(HGSOC). Methods: In this case-control study, clinical parameters, including surgical and non-surgical associated factors, were collected and compared between the patients with short-term (<2 years) and long-term (>5 years) survival who all underwent primary debulking surgery (PDS) followed by carboplatin and paclitaxel chemotherapy from January 2004 to December 2016. Univariate analysis was examined by chi-square test and multivariate analysis was performed by logistic regression analysis. Results: There were 95 cases long-term survival (LTS group) and 77 cases short-term survival (STS group) in 698 newly diagnosed HGSOC patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅲc and Ⅳ who met include and exclude criteria. (1) Univariate analysis showed that the proportion of complete cytoreduction with no visible residual disease (R0) at PDS and platinum sensitivity in LTS group were significantly higher than those in STS group (P<0.01). The surgical complexity score (SCS), the preoperative serum CA125 level and the ascites volume in the LTS group were significantly lower than those of the STS group (all P<0.05). In the LTS group, the preoperative incidence of lesions in retrograde peritoneum of the bladder, serosal and mesangial membrane of the small intestine, upper abdominal peritoneum and liver parenchyma were significantly lower than those in the STS group (all P<0.05). Multivariate logistic regression analysis showed that platinum sensitivity (OR=0.016, 95%CI: 0.004-0.063, P<0.01), ascites volume >500 ml (OR=3.193, 95%CI: 1.285-7.930, P=0.012), and SCS ≥8 (OR=17.433, 95%CI: 2.281-133.25, P=0.003) were independent factors affecting long-term survival (P>0.05). (2) Totally 37 of 95 in long-term survival and 16 of 77 in short-term survival achieved R0 cytoreduction at PDS. Univariate analysis showed that preoperative serum CA125 level, preoperative lesion score, preoperative lesion (DS) score, ascites volume, platinum sensitivity,and SCS were significantly correlated with the R0 PDS (all P<0.05). Multivariate analysis showed that ascites volume >500 ml (OR=5.199, 95%CI: 2.015-13.409, P=0.001), DS >2 (OR=15.264, 95%CI: 5.843-39.874, P<0.01) and SCS ≥4 (OR=4.176, 95%CI: 1.618-10.777, P=0.003) were independent factors associated with R0 cytoreduction. In patients with DS ≤2 or SCS <4, but not those with DS >2 or SCS ≥4, R0 cytoreduction was significantly associated with long-term survival. Conclusion: The intrinsic biology of tumor is the factor influencing long-term survival of advanced HGSOC patients, and those who present with wide intraperitoneal metastases and need to remove multiple organs may not benefit from R0 cytoreduction.

Management challenges in low-grade serous ovarian cancer with a BRCA mutation

BRCA mutations in the manifestation and treatment of ovarian cancer.

Targeted Therapies in Low-Grade Serous Ovarian Cancers

What Influences the Long-Term Survival of Advanced High-Grade Serous Ovarian Cancer?

BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study

Recurrent low-grade uterine sarcoma: a diagnostic and therapeutic challenge

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy

[Current management of advanced high grade serous ovarian carcinomas]

Genetic Disorders Requiring Risk-Reducing Surgical Management in Our Gynecological Oncology Practice

Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review

The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance

Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science

Prognostic And Therapeutic Factors For Low-Grade Serous Ovarian Carcinoma: A Multicentric, Retrospective Study Of The Turkish Society Of Gynaecologic Oncology

A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role

The BRCA Gene in Epithelial Ovarian Cancer

The Challenges of Managing Ovarian Cancer in the Developing World

Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?

Advances in precision therapy of low-grade serous ovarian cancer: A review

Primary ovarian cancer combined with primary fallopian tube cancer: A case report